RT Journal Article
T1 Detoxifying antitumoral drugs via nanoconjugation: the case of gold nanoparticles and cisplatin
A1 Comenge, Joan
A1 Sotelo Goyanes, María Carmen
A1 Romero, Francisco
A1 Gallego, Óscar
A1 Barnadas, Agustí
A1 García-Caballero Parada, Tomás
A1 Domínguez Puente, Fernando Ignacio
A1 Puntes, Víctor F.
AB Nanoparticles (NPs) have emerged as a potential tool to improve cancer treatment. Among the proposed uses in imaging and therapy, their use as a drug delivery scaffold has been extensively highlighted. However, there are still some controversial points which need a deeper understanding before clinical application can occur. Here the use of gold nanoparticles (AuNPs) to detoxify the antitumoral agent cisplatin, linked to a nanoparticle via a pH-sensitive coordination bond for endosomal release, is presented. The NP conjugate design has important effects on pharmacokinetics, conjugate evolution and biodistribution and results in an absence of observed toxicity. Besides, AuNPs present unique opportunities as drug delivery scaffolds due to their size and surface tunability. Here we show that cisplatin-induced toxicity is clearly reduced without affecting the therapeutic benefits in mice models. The NPs not only act as carriers, but also protect the drug from deactivation by plasma proteins until conjugates are internalized in cells and cisplatin is released. Additionally, the possibility to track the drug (Pt) and vehicle (Au) separately as a function of organ and time enables a better understanding of how nanocarriers are processed by the organism.
PB PLOS
YR 2012
FD 2012
LK http://hdl.handle.net/10347/21969
UL http://hdl.handle.net/10347/21969
LA eng
NO Comenge J, Sotelo C, Romero F, Gallego O, Barnadas A, Parada TG-C, et al. (2012) Detoxifying Antitumoral Drugs via Nanoconjugation: The Case of Gold Nanoparticles and Cisplatin. PLoS ONE 7(10): e47562. https://doi.org/10.1371/journal.pone.0047562
NO The authors acknowledge financial support from the grants “Plan Nacional” (MAT2009-14734-C02-01 and MAT2009-14734-C02-02) and NANOBIOMED-CONSOLIDER (CSD2006-00012) from the Spanish Government. Also grants VALTEC09-2-0085, VALTEC09-2-0089, and 2009-SGR-776 from the Catalan Government
DS Minerva
RD 30 abr 2026